JP2008515775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515775A5 JP2008515775A5 JP2007525855A JP2007525855A JP2008515775A5 JP 2008515775 A5 JP2008515775 A5 JP 2008515775A5 JP 2007525855 A JP2007525855 A JP 2007525855A JP 2007525855 A JP2007525855 A JP 2007525855A JP 2008515775 A5 JP2008515775 A5 JP 2008515775A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- years
- stable
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 | |
| US60/601,311 | 2004-08-13 | ||
| PCT/US2005/028861 WO2006020935A2 (en) | 2004-08-13 | 2005-08-12 | Stabilizing formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515775A JP2008515775A (ja) | 2008-05-15 |
| JP2008515775A5 true JP2008515775A5 (https=) | 2011-11-10 |
| JP4948407B2 JP4948407B2 (ja) | 2012-06-06 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525855A Expired - Fee Related JP4948407B2 (ja) | 2004-08-13 | 2005-08-12 | 安定化処方 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (https=) |
| EP (1) | EP1784219B1 (https=) |
| JP (1) | JP4948407B2 (https=) |
| KR (1) | KR20070092197A (https=) |
| CN (1) | CN101022831A (https=) |
| AR (1) | AR051009A1 (https=) |
| AU (1) | AU2005272603A1 (https=) |
| BR (1) | BRPI0514340A (https=) |
| CA (1) | CA2575870A1 (https=) |
| CR (1) | CR8904A (https=) |
| EC (1) | ECSP077246A (https=) |
| ES (1) | ES2637854T3 (https=) |
| IL (1) | IL181265A0 (https=) |
| MX (1) | MX2007001599A (https=) |
| NO (1) | NO20070930L (https=) |
| RU (1) | RU2007109062A (https=) |
| TW (1) | TW200621282A (https=) |
| WO (1) | WO2006020935A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| AU2007240732B2 (en) * | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| AR060487A1 (es) | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| RU2476442C2 (ru) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Кристаллические антитела против il-12 человека |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| LT2805731T (lt) | 2009-09-03 | 2019-02-11 | Ablynx N.V. | Stabilios polipeptidų kompozicijos ir jų panaudojimas |
| CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr：fc-融合多肽组合物及使用方法 |
| KR102143482B1 (ko) | 2011-11-30 | 2020-08-11 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법 |
| EP4527855A3 (en) * | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| JP2016540826A (ja) | 2013-11-04 | 2016-12-28 | ファイザー・インク | 抗ｅｆｎａ４抗体−薬物コンジュゲート |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| EP3194977B1 (en) * | 2014-07-21 | 2019-10-02 | Unchained Labs | Determination of protein aggregation from the concentration dependence of delta g |
| KR20250152679A (ko) | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| WO2018035470A1 (en) | 2016-08-18 | 2018-02-22 | Regeneron Pharmaceuticals, Inc. | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形性形態 |
| MX2020013713A (es) | 2018-07-04 | 2021-03-02 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
| EP3924328A1 (en) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| AU2021262609A1 (en) * | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| KR20230131212A (ko) * | 2021-01-14 | 2023-09-12 | 한올바이오파마주식회사 | 안정화제를 사용하지 않고도 안정한, 탄파너셉트를포함하는 안과용 조성물 |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0041768B1 (en) | 1980-04-24 | 1987-11-11 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6852703B1 (en) | 1997-06-04 | 2005-02-08 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| WO2001047554A1 (fr) * | 1999-12-28 | 2001-07-05 | Chugai Seiyaku Kabushiki Kaisha | Compositions d'anticorps stables et preparations pour injection |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| AU2003201824A1 (en) * | 2002-01-03 | 2003-07-24 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
| SG187991A1 (en) | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| CN1671741A (zh) * | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| JP2007528868A (ja) | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスｙ抗イディオタイプ抗体およびその使用 |
| SV2007002227A (es) | 2004-09-10 | 2007-03-20 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en not_active Expired - Lifetime
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Withdrawn
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es not_active Expired - Lifetime
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en not_active Ceased
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja not_active Expired - Fee Related
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515775A5 (https=) | ||
| RU2007109062A (ru) | Стабилизирующие препараты | |
| Arakawa et al. | Biotechnology applications of amino acids in protein purification and formulations | |
| ES2338218T3 (es) | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. | |
| S Rajan et al. | Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases | |
| KR101195295B1 (ko) | 고농도 항체 및 단백질 제형 | |
| JP2010513522A5 (https=) | ||
| JP2016534052A5 (https=) | ||
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| WO2007147001A3 (en) | Lyophilized formulations of anti-egfr antibodies | |
| JP6253161B2 (ja) | 乾燥された生物学的材料を安定化するための方法及び組成物 | |
| WO2008116103A3 (en) | Stable antibody formulations | |
| JP2024506940A5 (https=) | ||
| AR069860A1 (es) | Metodo para purificar un anticuerpo cd20 | |
| JP2009527251A5 (https=) | ||
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| JO3449B1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
| CN109925284A (zh) | 肉毒杆菌毒素冻干制剂 | |
| JP2013531679A5 (https=) | ||
| JP2007534698A5 (https=) | ||
| RU2009120200A (ru) | Препараты с высокими концентрациями белка, содержащие маннитол | |
| JP2016520075A5 (https=) | ||
| WO2006094974A3 (en) | Chemically defined stabiliser composition | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция |